Ceftazidime

Usual Dosing (Adults)

1-2 grams IV q8-12 hours.
[Severe]: 2 grams q8 hours.

Recommended Dosage Schedule

	Dose	Frequency
Adults
Usual recommended dosage	1 gram IV or IM	q8-12hr
Uncomplicated urinary tract infections	250 mg IV or IM	q12hr
Bone and joint infections	2 grams IV	q12hr
Complicated urinary tract infections	500 mg IV or IM	q8-12hr
Uncomplicated pneumonia; mild skin and skin-structure infections	500 mg-1 gram IV or IM	q8hr
Serious gynecologic and intra-abdominal infections	2 grams IV	q8hr
Meningitis	2 grams IV	q8hr
Very severe life-threatening infections, especially in immunocompromised patients	2 grams IV	q8hr
Lung infections caused by Pseudomonas spp. in patients with cystic fibrosis with normal renal function*	30-50 mg/kg IV to a maximum of 6 grams per day	q8hr
Neonates (0-4 weeks)	30 mg/kg IV	q12hr
Infants and children (1 month-12 years)	30-50 mg/kg IV to a maximum of 6 grams per day†	q8hr

* Although clinical improvement has been shown, bacteriologic cures cannot be expected in patients with chronic respiratory disease and cystic fibrosis.

†The higher dose should be reserved for immunocompromised pediatric patients or pediatric patients with cystic fibrosis or meningitis.

Renal Dosing

[CRCL >50 ]: No changes.

[31-50 ]: 1 gram q12h.

[16-30 ]: 1 gram q24h.

[6-15 ]: 500 mg q24h.

[<5 –dialysis]: 500 mg q48h.
Note: all dosages listed for renal insufficiency may be increased by 50% in severe infections.

Hemodialysis

Hemodialysis:
Loading dose: 1 gram x 1, then 1 gram after each hemodialysis session.
[Alternatively]: Give 1 gram q48h, plus give an additional 1 gram dose after each dialysis session.

CAPD: 1 gram x 1, followed by 500mg q24h.

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.